Global Biologics Drug Development Market
Global Biologics Drug Development Market

Biologics Drug Development Comprehensive Study by Type (Clinical Manufacturing, Formulation Development, Bioassay Development, Analytical Services), Application (In-House, Outsource, Pharma Excess) Players and Region - Global Market Outlook to 2026

Biologics Drug Development Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jun 2021 Edition 216 Pages 177 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Biologics Drug Development Market Scope?
Biologics products are subjected to varied laws and laws that affect patenting, testing, safety, efficacy, and promotion. Biologics products are isolated from natural sources like humans, animals, and microorganisms through biotechnological strategies and the newest technologies. Biosimilars should have similar safety and efficacy compared to the reference biological product. The biologics market contains biologics and biosimilar medication through oral, IV, and other delivery routes for treating chronic diseases.

The Biologics Drug Development market study is being classified by Type (Clinical Manufacturing, Formulation Development, Bioassay Development and Analytical Services), by Application (In-House, Outsource and Pharma Excess) and major geographies with country level break-up.

Growth in the historic period resulted from an aging population, government initiatives, the ability to command high prices, and an increased need for immunology. Factors that negatively affected growth in the historic period were pricing pressures from regulators, and lack of awareness on biosimilars among primary care physicians and specialists. Research Analyst at AMA predicts that Players from United States will contribute to the maximum growth of Global Biologics Drug Development market throughout the predicted period.

Pfizer Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (United States), Merck & Co., Inc. (United States), Johnson & Johnson (United States), Bristol Myers Squibb Company (United States), GlaxoSmithKline Plc. (United Kingdom), Amgen Inc. (United States), Sanofi S.A. (France), Eli Lilly and Company (United States), Wockhardt (India) and Zydus Cadilla (India) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Biologics Drug Development market by Type, Application and Region.

On the basis of geography, the market of Biologics Drug Development has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Influencing Market Trend
  • Robust Research & Development
  • Demand For Biologics in The Treatment of Complex Diseases

Market Drivers
  • Increasing Funding for Development
  • Increase In Healthcare Access

Opportunities
  • Research And Development Activities for Development of Oral Biologics
  • Initiatives From the Government

Restraints
  • Stringent Regulations Related to Biosimilar Approvals

Challenges
  • Presence Of Competitors


Key Target Audience
Manufacturers of Biologics Drug Development, Suppliers and distributors of Biologics Drug Development, Governmental and Regulatory bodies and End-Users

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Report Objectives / Segmentation Covered
By Type
  • Clinical Manufacturing
  • Formulation Development
  • Bioassay Development
  • Analytical Services
By Application
  • In-House
  • Outsource
  • Pharma Excess
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Funding for Development
      • 3.2.2. Increase In Healthcare Access
    • 3.3. Market Challenges
      • 3.3.1. Presence Of Competitors
    • 3.4. Market Trends
      • 3.4.1. Robust Research & Development
      • 3.4.2. Demand For Biologics in The Treatment of Complex Diseases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Biologics Drug Development, by Type, Application and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Biologics Drug Development (Value)
      • 5.2.1. Global Biologics Drug Development by: Type (Value)
        • 5.2.1.1. Clinical Manufacturing
        • 5.2.1.2. Formulation Development
        • 5.2.1.3. Bioassay Development
        • 5.2.1.4. Analytical Services
      • 5.2.2. Global Biologics Drug Development by: Application (Value)
        • 5.2.2.1. In-House
        • 5.2.2.2. Outsource
        • 5.2.2.3. Pharma Excess
      • 5.2.3. Global Biologics Drug Development Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Biologics Drug Development (Price)
      • 5.3.1. Global Biologics Drug Development by: Type (Price)
  • 6. Biologics Drug Development: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AbbVie Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bristol Myers Squibb Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Amgen Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi S.A. (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eli Lilly and Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Wockhardt (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Zydus Cadilla (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Biologics Drug Development Sale, by Type, Application and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Biologics Drug Development (Value)
      • 7.2.1. Global Biologics Drug Development by: Type (Value)
        • 7.2.1.1. Clinical Manufacturing
        • 7.2.1.2. Formulation Development
        • 7.2.1.3. Bioassay Development
        • 7.2.1.4. Analytical Services
      • 7.2.2. Global Biologics Drug Development by: Application (Value)
        • 7.2.2.1. In-House
        • 7.2.2.2. Outsource
        • 7.2.2.3. Pharma Excess
      • 7.2.3. Global Biologics Drug Development Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Biologics Drug Development (Price)
      • 7.3.1. Global Biologics Drug Development by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Biologics Drug Development: by Type(USD Million)
  • Table 2. Biologics Drug Development Clinical Manufacturing , by Region USD Million (2015-2020)
  • Table 3. Biologics Drug Development Formulation Development , by Region USD Million (2015-2020)
  • Table 4. Biologics Drug Development Bioassay Development , by Region USD Million (2015-2020)
  • Table 5. Biologics Drug Development Analytical Services , by Region USD Million (2015-2020)
  • Table 6. Biologics Drug Development: by Application(USD Million)
  • Table 7. Biologics Drug Development In-House , by Region USD Million (2015-2020)
  • Table 8. Biologics Drug Development Outsource , by Region USD Million (2015-2020)
  • Table 9. Biologics Drug Development Pharma Excess , by Region USD Million (2015-2020)
  • Table 10. South America Biologics Drug Development, by Country USD Million (2015-2020)
  • Table 11. South America Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 12. South America Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 13. Brazil Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 14. Brazil Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 15. Argentina Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 16. Argentina Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 17. Rest of South America Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 18. Rest of South America Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 19. Asia Pacific Biologics Drug Development, by Country USD Million (2015-2020)
  • Table 20. Asia Pacific Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 21. Asia Pacific Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 22. China Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 23. China Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 24. Japan Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 25. Japan Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 26. India Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 27. India Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 28. South Korea Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 29. South Korea Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 30. Taiwan Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 31. Taiwan Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 32. Australia Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 33. Australia Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 34. Rest of Asia-Pacific Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 35. Rest of Asia-Pacific Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 36. Europe Biologics Drug Development, by Country USD Million (2015-2020)
  • Table 37. Europe Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 38. Europe Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 39. Germany Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 40. Germany Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 41. France Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 42. France Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 43. Italy Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 44. Italy Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 45. United Kingdom Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 46. United Kingdom Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 47. Netherlands Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 48. Netherlands Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 49. Rest of Europe Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 50. Rest of Europe Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 51. MEA Biologics Drug Development, by Country USD Million (2015-2020)
  • Table 52. MEA Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 53. MEA Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 54. Middle East Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 55. Middle East Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 56. Africa Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 57. Africa Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 58. North America Biologics Drug Development, by Country USD Million (2015-2020)
  • Table 59. North America Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 60. North America Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 61. United States Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 62. United States Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 63. Canada Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 64. Canada Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 65. Mexico Biologics Drug Development, by Type USD Million (2015-2020)
  • Table 66. Mexico Biologics Drug Development, by Application USD Million (2015-2020)
  • Table 67. Biologics Drug Development: by Type(USD/Units)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Biologics Drug Development: by Type(USD Million)
  • Table 81. Biologics Drug Development Clinical Manufacturing , by Region USD Million (2021-2026)
  • Table 82. Biologics Drug Development Formulation Development , by Region USD Million (2021-2026)
  • Table 83. Biologics Drug Development Bioassay Development , by Region USD Million (2021-2026)
  • Table 84. Biologics Drug Development Analytical Services , by Region USD Million (2021-2026)
  • Table 85. Biologics Drug Development: by Application(USD Million)
  • Table 86. Biologics Drug Development In-House , by Region USD Million (2021-2026)
  • Table 87. Biologics Drug Development Outsource , by Region USD Million (2021-2026)
  • Table 88. Biologics Drug Development Pharma Excess , by Region USD Million (2021-2026)
  • Table 89. South America Biologics Drug Development, by Country USD Million (2021-2026)
  • Table 90. South America Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 91. South America Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 92. Brazil Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 93. Brazil Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 94. Argentina Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 95. Argentina Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 96. Rest of South America Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 97. Rest of South America Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 98. Asia Pacific Biologics Drug Development, by Country USD Million (2021-2026)
  • Table 99. Asia Pacific Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 100. Asia Pacific Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 101. China Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 102. China Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 103. Japan Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 104. Japan Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 105. India Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 106. India Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 107. South Korea Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 108. South Korea Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 109. Taiwan Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 110. Taiwan Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 111. Australia Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 112. Australia Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 113. Rest of Asia-Pacific Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 114. Rest of Asia-Pacific Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 115. Europe Biologics Drug Development, by Country USD Million (2021-2026)
  • Table 116. Europe Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 117. Europe Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 118. Germany Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 119. Germany Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 120. France Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 121. France Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 122. Italy Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 123. Italy Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 124. United Kingdom Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 125. United Kingdom Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 126. Netherlands Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 127. Netherlands Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 128. Rest of Europe Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 129. Rest of Europe Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 130. MEA Biologics Drug Development, by Country USD Million (2021-2026)
  • Table 131. MEA Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 132. MEA Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 133. Middle East Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 134. Middle East Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 135. Africa Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 136. Africa Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 137. North America Biologics Drug Development, by Country USD Million (2021-2026)
  • Table 138. North America Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 139. North America Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 140. United States Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 141. United States Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 142. Canada Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 143. Canada Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 144. Mexico Biologics Drug Development, by Type USD Million (2021-2026)
  • Table 145. Mexico Biologics Drug Development, by Application USD Million (2021-2026)
  • Table 146. Biologics Drug Development: by Type(USD/Units)
  • Table 147. Research Programs/Design for This Report
  • Table 148. Key Data Information from Secondary Sources
  • Table 149. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Biologics Drug Development: by Type USD Million (2015-2020)
  • Figure 5. Global Biologics Drug Development: by Application USD Million (2015-2020)
  • Figure 6. South America Biologics Drug Development Share (%), by Country
  • Figure 7. Asia Pacific Biologics Drug Development Share (%), by Country
  • Figure 8. Europe Biologics Drug Development Share (%), by Country
  • Figure 9. MEA Biologics Drug Development Share (%), by Country
  • Figure 10. North America Biologics Drug Development Share (%), by Country
  • Figure 11. Global Biologics Drug Development: by Type USD/Units (2015-2020)
  • Figure 12. Global Biologics Drug Development share by Players 2020 (%)
  • Figure 13. Global Biologics Drug Development share by Players (Top 3) 2020(%)
  • Figure 14. Global Biologics Drug Development share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 18. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 20. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 25. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 26. Bristol Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. Bristol Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 28. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2020
  • Figure 30. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 32. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 33. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 34. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 35. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 36. Wockhardt (India) Revenue, Net Income and Gross profit
  • Figure 37. Wockhardt (India) Revenue: by Geography 2020
  • Figure 38. Zydus Cadilla (India) Revenue, Net Income and Gross profit
  • Figure 39. Zydus Cadilla (India) Revenue: by Geography 2020
  • Figure 40. Global Biologics Drug Development: by Type USD Million (2021-2026)
  • Figure 41. Global Biologics Drug Development: by Application USD Million (2021-2026)
  • Figure 42. South America Biologics Drug Development Share (%), by Country
  • Figure 43. Asia Pacific Biologics Drug Development Share (%), by Country
  • Figure 44. Europe Biologics Drug Development Share (%), by Country
  • Figure 45. MEA Biologics Drug Development Share (%), by Country
  • Figure 46. North America Biologics Drug Development Share (%), by Country
  • Figure 47. Global Biologics Drug Development: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Pfizer Inc. (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
  • AbbVie Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Johnson & Johnson (United States)
  • Bristol Myers Squibb Company (United States)
  • GlaxoSmithKline Plc. (United Kingdom)
  • Amgen Inc. (United States)
  • Sanofi S.A. (France)
  • Eli Lilly and Company (United States)
  • Wockhardt (India)
  • Zydus Cadilla (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation